Program
ZE66-0205
A development code.
Its studies are led by Eilean Therapeutics.
Furthest: phase 1, since Jul 24, 20261 company-led study, 1 open or runningNext primary completion: Aug 15, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eilean Therapeutics | 11 open or running | phase 1since Jul 24, 2026 | Jul 24, 2026 | Aug 15, 2027phase 1 · NCT07735728 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 24, 2026First study: phase 1 study in Healthy Volunteers (HV)First studyNCT07735728 · 32 planned · Australia
Ahead
- Aug 15, 2027Primary completion: phase 1 study in Healthy Volunteers (HV)NCT07735728
TargetBeta
MALT1 →read by rule
“The study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ZE66-0205, a novel orally administered small-molecule degrader of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1).”study text, by rule · the study
Other programs on MALT1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| safimaltibrule | Johnson & Johnson | phase 1 | 4 |
| CARD11-BCL10-MALT1 Complex Inhibitor XL114rule | Dr. Reddy's Laboratories | phase 1 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07735728Healthy Volunteers (HV) · Australia | 1 | Recruiting | Aug 15, 2027 | 32 |
How it is read
Names in the registry
- “ZE66-0205”, 1 entry
Codes read as this program: ZE660205.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.